The Adiponectin Receptor Protein 1 pipeline drugs market research report outlays comprehensive information on the Adiponectin Receptor Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Adiponectin Receptor Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Ophthalmology, Metabolic Disorders, Cardiovascular, and Gastrointestinal which include the indications Keratoconjunctivitis Sicca (Dry Eye), Ophthalmology, Obesity, Type 2 Diabetes, Cardiovascular Disease, and Metabolic Dysfunction-Associated Steatohepatitis (MASH). It also reviews key players involved in Adiponectin Receptor Protein 1 targeted therapeutics development with respective active and dormant or discontinued products.

The Adiponectin Receptor Protein 1 pipeline targets constitutes close to eight molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, and Discovery stages are 1, 1, 2, and 3 respectively.

Adiponectin Receptor Protein 1 overview

Adiponectin receptor protein 1 (ADIPOR1) is a receptor for adiponectin, a hormone secreted by adipocytes that regulates fatty acid catabolism and glucose levels. ADIPOR1 has high affinity for globular adiponectin and low affinity for full-length adiponectin. ADIPOR1 binds to ADIPOQ, which activates a signaling cascade that leads to increased AMPK activity, and ultimately to increased fatty acid oxidation, increased glucose uptake, and decreased gluconeogenesis.

For a complete picture of Adiponectin Receptor Protein 1’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.